Northern Trust Corp Zymeworks Inc. Transaction History

Northern Trust Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $9,858 - $15,751	2,120 Added 17.5%	14,235 $88,000
Q2 2022 Aug 12, 2022	SELL	$4.82 - $7.7 $162,361 - $259,374	-33,685 Reduced 73.55%	12,115 $64,000
Q1 2022 May 13, 2022	SELL	$6.0 - $16.98 $3,804 - $10,765	-634 Reduced 1.37%	45,800 $300,000
Q4 2021 Feb 08, 2022	SELL	$15.19 - $29.33 $759 - $1,466	-50 Reduced 0.11%	46,434 $762,000
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $5.46 Million - $7.45 Million	-199,723 Reduced 81.12%	46,484 $1.35 Million
Q2 2021 Aug 13, 2021	BUY	$26.5 - $38.23 $5.45 Million - $7.86 Million	205,639 Added 506.9%	246,207 $8.54 Million
Q1 2021 May 12, 2021	SELL	$29.83 - $56.81 $267,903 - $510,210	-8,981 Reduced 18.13%	40,568 $1.28 Million
Q4 2020 Feb 11, 2021	SELL	$39.12 - $54.99 $99,521 - $139,894	-2,544 Reduced 4.88%	49,549 $2.34 Million
Q3 2020 Nov 16, 2020	BUY	$29.21 - $46.58 $22,900 - $36,518	784 Added 1.53%	52,093 $2.43 Million
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $1.39 Million - $1.66 Million	41,391 Added 417.33%	51,309 $1.85 Million
Q1 2020 May 14, 2020	BUY	$24.28 - $49.8 $3,860 - $7,918	159 Added 1.63%	9,918 $352,000
Q4 2019 Feb 14, 2020	BUY	$24.84 - $45.46 $242,413 - $443,644	9,759 New	9,759 $444,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $949M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.